Approximately one-third of patients achieved 25% or greater weight loss
Like my patient who quit smoking after a lifetime of trying, it happened without effort
In post-hoc analyses at 24 weeks, the last time point before placebo participants were eligible for orforglipron as rescue therapy, the change in body weight from ATTAIN-MAINTAIN baseline for patients switching to orforglipron from Wegovy was -0.1 kg vs
Human clinical trials, though limited, have demonstrated a potential decrease in substance use among patients treated with GLP-1RAs, particularly for alcohol and tobacco use disorders
Overall, mycotoxin testing supports a holistic, evidence-based path to better health
Someone with obesity and obstructive sleep apnea may require larger, sustained weight loss and thus choose a prescription GLP-1 like Ozempic (injectable) under medical supervision